Virax Biolabs

About:

Virax Biolabs is a biotechnology company focusing on the prevention, detection, and diagnosis of viral diseases.

Website: http://viraxbiolabs.com

Description:

Virax Biolabs is a biotechnology company focusing on the prevention, detection, and diagnosis of viral diseases. Virax is a revenue-generating group established in 2013 whose primary business is the proprietary development and global distribution of in vitro diagnostic (IVD) test kits. Virax Biolabs is developing an immunology platform based on T-Cell testing. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria & Human Papilloma Virus. Virax Biolabs’ vision is to facilitate the transition into the 'new normal’ during and post-pandemic through the provision of the latest medical equipment and technology. Virax Biolabs is acquiring innovative biosensor technology from which it intends to develop into novel point-of-care biomarker testing devices, that rival lab-based ELISA tests for accuracy.

Total Funding Amount:

$16.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2013-03-11

Contact Email:

info(AT)viraxbiolabs.com

Founders:

Cameron Shaw, Greg Aldridge, James Foster, Mark Ternouth, Tomasz George

Number of Employees:

11-50

Last Funding Date:

2024-08-21

IPO Status:

Public

Industries:

© 2025 bioDAO.ai